Legend Biotech (NASDAQ:LEGN) is a global biotech firm focused on discovering, developing, and commercializing cell therapies for oncology and other life-threatening diseases. Their robust pipeline includes candidate treatments that leverage innovative technologies, particularly in the realm of CAR-T cell therapies aimed at improving patient outcomes in areas of high unmet need. One of their notable projects is the advancement of therapies targeting multiple myeloma, showcasing their commitment to pushing the boundaries of medicine. With a mission to transform the lives of patients by harnessing the power of cutting-edge science, Legend Biotech is dedicated to achieving breakthroughs that could redefine treatment paradigms. The company's work spans multiple continents, reflecting its global approach to tackling critical healthcare challenges.